Share
research

Stanford achieves COMPLETE memory restoration in AD models by blocking metabolic switch + 75% patients have hidden sleep apnea (and it's consequences!)

Wednesday plenary from the AAIC, fresh from July 2025.

5 min read

Key Takeaway

Stanfords Dr. Andreasson achieved complete memory restoration in Alzheimer models by blocking the IDO1 enzyme that starves neurons of glucose. Separately, Professor Naismith at Sydney found 75 percent of memory clinic patients have undiagnosed sleep apnea, and one bad night impairs toxic protein clearance for two days. Both findings point to treatable upstream mechanisms.

Definition

An enzyme that regulates tryptophan metabolism and, when overactive, disrupts brain glucose metabolism in Alzheimer disease.

IDO1 inhibitors have cleared safety trials for other indications, creating a potential fast track toward testing them as Alzheimer treatments based on Dr. Andreassons Stanford findings.

Definition

The brains overnight waste-removal system that flushes amyloid, tau, and other toxins during deep sleep.

Sleep apnea, poor sleep, and fragmented sleep architecture all impair glymphatic function. A single bad night can reduce toxic protein clearance for up to two days.

Treatable Mechanisms Highlighted at AAIC 2025

MechanismDiscoveryAvailable treatment
IDO1-driven neuron starvationStanford - complete memory restoration in AD modelsIDO1 inhibitors (safety trials passed)
Undiagnosed sleep apneaSydney - 75 percent of memory clinic patients affectedCPAP therapy
Sleep-related tau accumulationPoor sleep impairs toxic protein clearanceDORA class sleep medications
Stanford achieves COMPLETE memory restoration in AD models by blocking metabolic switch + 75% patients have hidden sleep apnea (and it's consequences!)

Evidence-Based Content

Reviewed by Dr. Kevin Tran, PharmD · Based on peer-reviewed research · Updated

Updated recently

Key Takeaway

Breakthrough Stanford research reveals key to memory restoration: Blocking metabolic switch and addressing hidden sleep apnea could revolutionize Alzheimer's prevention strategies. Important for APOE4 carriers to optimize sleep.

Categories

research
Dr. Kevin Tran
About the Author

Dr. Kevin Tran

PharmD

Dr. Kevin Tran is a Doctor of Pharmacy and APOE4/4 carrier dedicated to helping others with the APOE4 gene variant take proactive steps for their health. He founded The Phoenix Community to provide evidence-based resources and support for APOE4 carriers.

View all articles

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

Frequently Asked Questions

What did Stanford discover about memory loss in Alzheimer disease?
Dr. Katrin Andreasson at Stanford University presented findings at AAIC 2025 showing that neurons in Alzheimer disease are not dying, they are starving. An enzyme called IDO1 hijacks the brains glucose metabolism, depriving neurons of energy. When her team blocked IDO1 in animal models, they achieved complete memory restoration, not merely improvement. The finding reframes Alzheimer as a metabolic disease at its core and opens a new therapeutic direction. Critically, IDO1 inhibitors have already passed safety trials for other indications, which could accelerate translation.
Why is sleep apnea so important for Alzheimer prevention?
Professor Sharon Naismith at the University of Sydney reported that 75 percent of memory clinic patients have undiagnosed sleep apnea. Every episode of nighttime oxygen deprivation damages the brain. One bad night of sleep impairs toxic protein clearance for two days because the glymphatic system relies on deep sleep to flush amyloid and tau. For APOE4 carriers, whose baseline amyloid clearance is already compromised, untreated sleep apnea may dramatically accelerate pathology. Getting screened is a high-leverage intervention.
Does CPAP therapy protect against cognitive decline?
Yes. According to the AAIC 2025 presentation, continuous positive airway pressure therapy protects against cognitive decline in patients with sleep apnea. By maintaining oxygen levels and restoring deep sleep, CPAP supports the glymphatic clearance system that flushes amyloid and tau from the brain. For APOE4 carriers with sleep apnea, consistent CPAP use may be one of the highest-impact prevention steps available, especially given how common undiagnosed sleep apnea is in this population.
What is IDO1 and how does it affect brain metabolism?
IDO1, or indoleamine 2,3-dioxygenase 1, is an enzyme involved in tryptophan metabolism and immune regulation. Dr. Andreassons Stanford research showed that in Alzheimer models, IDO1 becomes overactive in the brain and disrupts hippocampal glucose metabolism, effectively starving neurons of the fuel they need to function. Blocking IDO1 restored glucose metabolism and rescued cognition. Because IDO1 inhibitors have already cleared safety trials for other indications, there is a plausible path to testing them in APOE4 carriers and Alzheimer patients.
What are DORA drugs and how do they affect tau?
DORAs, or dual orexin receptor antagonists, are a newer class of sleep medications. Beyond improving sleep quality, research presented at AAIC 2025 suggests DORAs can reduce tau protein levels in the brain. This is a meaningful finding because tau tangles are one of the two core pathologies of Alzheimer disease. For APOE4 carriers struggling with sleep and tau accumulation, DORAs may eventually become a dual-purpose tool, though more research specific to APOE4 carriers is still needed.
Keep Reading

Related Protocols for You

More about research